GX 051

Drug Profile

GX 051

Alternative Names: GX-051; GX-51

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genexine
  • Class Cancer vaccines; Cell therapies; Gene therapies; Stem cell therapies
  • Mechanism of Action Angiogenesis inhibitors; CD8 positive T lymphocyte stimulants; Immunostimulants; Interferon gamma stimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Head and neck cancer

Most Recent Events

  • 28 Mar 2018 Discontinued - Phase-I for Head and neck cancer (Late-stage disease) in South Korea (Intratumoural) (Genexine pipeline, March 2018)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Head-and-neck-cancer(Late-stage disease) in South Korea (Intratumoural, Injection)
  • 01 Mar 2014 Phase-I clinical trials in Head and neck cancer (late-stage disease) in South Korea (Intratumoural) (NCT02079324)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top